This is a legacy content and is all our forum is now taking place on Discord.
Journal Club 23/01/2020 – Five-year Outcomes for a Prospective Randomised Controlled Trial Comparing Laparoscopic and Robot-assisted Radical Prostatectomy
Quote from Deleted user on 23rd January 2020, 7:17 pmTotal number = 9
BethCReply
Hi everyone
Won5:57 pm
Hello, I’m Won Young
leah.argus5:57 pm
Hi there, I’m Leah
dianaomari5:58 pm
Hi, I am DIana
dianaomari5:58 pm
Diana*
Dr Kirolos Michael5:59 pm
Hi everyone! We’ll start in a few minutes once more people have joined
Americos Argyriou6:01 pm
Could everyone please write down you name, Year of study, Hospital and email for our records and for Certificates of Attendance!
Americos Argyriou6:02 pm
Hey guys, I’m Americos, Intercalator 3rd/4th year, MRI, amerikos.argyriou@student.manchester.ac.uk
Won6:02 pm
I’m Won Young, Year 2, won.yoon@student.manchester.ac.uk
BethC6:02 pm
Beth, Year 4 Salford Royal, bethan.clayton@student.manchester.ac.uk
dianaomari6:03 pm
Hello, I’m Diana Al-Omari, 3rd year, MRI, diana.omari@student.manchester.ac.uk
leah.argus6:03 pm
Leah, 4th year, MFT Wytheshawe, leah.argus@student.manchester.ac.uk
BethC6:04 pm
Has everyone read the paper? Was it an okay read?
dianaomari6:04 pm
Yes it was quite interesting
leah.argus6:04 pm
It’s quite clear in its aims and outcomes
Dr Kirolos Michael6:05 pm
I’m Kirolos, FY2 doctor at stepping hill
Dr Kirolos Michael6:05 pm
is everyone ready to make a start?
nmp246:05 pm
Nora, 4th year, SRFT, eleanor.palmer-2@student.manchester.ac.uk
leah.argus6:06 pm
I’m happy to get started
dianaomari6:06 pm
Me too
Dr Kirolos Michael6:06 pm
So the aim of these sessions is to give a taster into the world of medical research. Each session, we will look a different surgical speciality.
Dr Kirolos Michael6:07 pm
This week, I have chosen urology and selected a paper that looks at comparing robot-assisted vs. laparoscopic prostatectomy in terms of the 5yr outcome
Dr Kirolos Michael6:08 pm
Hopefully if was an interesting topic
Dr Kirolos Michael6:08 pm
Can anyone summarise the aim of the study?
leah.argus6:09 pm
It seems to be a prospective randomised study (1 year of data collection, n=120 patients, 5 years of follow up), comparing functional, oncological and patient satisfaction outcomes of robot assisted versus laparoscopic radical prostatectomy, finding improvement in functional outcomes for RARP
Dr Kirolos Michael6:10 pm
great
Dr Kirolos Michael6:12 pm
So a bit of background. Radical prostatectomy involves resecting the entirety of the prostate for localised prostate cancer, with curative intent. In the past, this used to be done as an open surgery, then laparoscopic surgery became favoured and most recently, robot-assisted prostatectomy is currently the Gold-standard. We even have a robot in urology centres like Stepping Hill where I work
Dr Kirolos Michael6:12 pm
What were the functional, oncological & patient satisfaction outcomes that they assessed?
dianaomari6:13 pm
continence, potency, PSA, were functional
dianaomari6:13 pm
satisfaction and general health status
dianaomari6:13 pm
and survival rates for the oncological aspect?
dianaomari6:13 pm
I think
Americos Argyriou6:14 pm
PSA would come under oncological too I think
leah.argus6:14 pm
they assessed biochemical recurrence free survival as a parameter
Dr Kirolos Michael6:14 pm
Good. So functional measures were continence and potency (i.e. ability to achieve a satisfactory erection)
Dr Kirolos Michael6:14 pm
How well things function afterwards
Dr Kirolos Michael6:15 pm
The PSA is more of an oncological marker of recurrence, that is the biochemical marker of recurrence
dianaomari6:15 pm
Makes sense
Dr Kirolos Michael6:16 pm
After surgery, follow up would involve prostate specific antigen levels (PSA). If they start rising, it is an indicator of recurrence.
Dr Kirolos Michael6:16 pm
We’ve already touched a little on the study type. Would someone like to summarise the methodology?
dianaomari6:17 pm
120 patients with prostate cancer were enrolled and randomly assigned to RARP or LRP
dianaomari6:18 pm
The same surgeon performed all the operations
Americos Argyriou6:18 pm
Single centre, single surgeon as well
Americos Argyriou6:18 pm
yeah
dianaomari6:18 pm
Yes
Dr Kirolos Michael6:19 pm
Very good.
leah.argus6:19 pm
That’s a bit of a limitation
Americos Argyriou6:19 pm
They also set guidelines for the type of stage tumour they’re including into the trial
Dr Kirolos Michael6:19 pm
So the key point is that this was a randomised-controlled trial. Single centre. Single surgeon.
Dr Kirolos Michael6:19 pm
So which tumours were only included?
Americos Argyriou6:20 pm
As in only T1-2 N0 M0
Dr Kirolos Michael6:20 pm
I agree about the limitation Leah, we’ll come onto that in a little bit
Dr Kirolos Michael6:20 pm
That’s right Americos. Does anyone know what that TNM staging means?
sharanniyan6:20 pm
grade, nodal involvement and distant metastasis?
Dr Kirolos Michael6:21 pm
That’s correct. But in terms of a T1-2, N0, M0 etc.?
sharanniyan6:22 pm
they didn’t have nodal involvement or distant metastasis and were fairly small tumours?
sharanniyan6:22 pm
small-medium size perhaps
Dr Kirolos Michael6:22 pm
absolutely
leah.argus6:22 pm
T1-2 means no extraprostatic involvement i think
Won6:22 pm
T1-2 would be 2cm, N0 would be negative lymph nodes, and M0 would be no distant metastases
Dr Kirolos Michael6:23 pm
They were confined to the prostate
leah.argus6:24 pm
Was this determined clinically or pathologically (pT) in the study?
Dr Kirolos Michael6:24 pm
So Won, the T in the TNM staging of prostate cancer doesn’t involve size. It is to do with if it is confined to the prostate or locally invasive into nearby structures or organs etc. The T is different for different cancers. In some it is to with the size of the tumour etc.
Won6:25 pm
Sure
Dr Kirolos Michael6:25 pm
Good question Leah. So int he study design, it says it was pathologically confirmed
Dr Kirolos Michael6:26 pm
So required a biopsy (usually transperineal these days, but transrectal in the past)
BethC6:26 pm
Are we ready to start?
BethC6:27 pm
Sorry my laptop hadn’t refreshed at all
Ashka6:27 pm
Hi it’s Ashka. Sorry for being late. Traffic was really bad from wigan
Americos Argyriou6:27 pm
hahaha
Americos Argyriou6:27 pm
(sorry Beth)
Dr Kirolos Michael6:27 pm
haha I thought I got the wrong start time for a second?
Dr Kirolos Michael6:27 pm
Shall we move on to the results
Dr Kirolos Michael6:28 pm
so does anyone have any questions about the study design & aims etc.?
BethC6:28 pm
Of course, sorry about that
Dr Kirolos Michael6:29 pm
can anyone summarise the functional differences?
leah.argus6:29 pm
Were variables like blood loss and length of hospital stay recorded? These could affect the superiority of either
sharanniyan6:30 pm
continence was significant
Dr Kirolos Michael6:30 pm
That’s right, continence was significant. Does any one have any numbers to hand, maybe can explain what they mean?
dianaomari6:31 pm
the probability of achieving continence over time was more than doubled in the RARP group compared to the LRP group (odds ratio [OR] 2.47; 95% confidence interval [CI] 1.15–5.31; p = 0.021).
Dr Kirolos Michael6:31 pm
Fantastic
sharanniyan6:31 pm
potency was doubled as well
leah.argus6:32 pm
Odds ratio here implies that patients undergoing RARP were 2.47x more likely to achieve continence, right?
sharanniyan6:32 pm
slightly more than doubled in fact
Dr Kirolos Michael6:32 pm
Is everyone up to date with what an odds ratio is?
sharanniyan6:32 pm
2.35x
Dr Kirolos Michael6:32 pm
Exactly
Dr Kirolos Michael6:32 pm
How do we calculate the odds ratio generally speaking?
leah.argus6:33 pm
Mantel-Cox regression is one way of doing it
BethC6:34 pm
I’m not entirely sure actually, could you explain if that’s okay?
Dr Kirolos Michael6:34 pm
That’s one way of analysing a hazard ratio not an odds ratio
Dr Kirolos Michael6:34 pm
So essentially
Americos Argyriou6:35 pm
Simplifying it down you can just do the fraction of those with continence in one arm and divide it by the fraction of those with continence in the other
Americos Argyriou6:35 pm
That’ll give you the OR
Dr Kirolos Michael6:36 pm
To calculate an odds ratio, you calculate the probability of event in group A and the probability of event in group B (odds of the event in each group). Then you divide the odds of your intervention group over the comparator group
Dr Kirolos Michael6:37 pm
So that is correct Americos
BethC6:37 pm
That makes sense thank you!
Americos Argyriou6:37 pm
I think you put it more clearly
sharanniyan6:37 pm
How is that different from a hazard ratio?
Ashka6:37 pm
Thank you
Dr Kirolos Michael6:37 pm
So as everyone has said, you are >2x more likely to be continent & potent with RARP vs LRP
Dr Kirolos Michael6:39 pm
So the hazard ratio is time dependent. It’s a time to event analysis that a little more complicated compared to the odds ratio. You are essentially seeing at a chosen point in time, what is the likely hood of the event occurring up to that particular time. The odds ratio doesn’t like at time. It is just the probability of it happening at all if that makes sense
sharanniyan6:39 pm
Oh I see, thank you
leah.argus6:39 pm
Thanks for clarifying
Dr Kirolos Michael6:40 pm
Great
Dr Kirolos Michael6:40 pm
How about in terms of the oncological outcomes like survival. Were there any differences between the two?
Americos Argyriou6:40 pm
Strange how the overall contience OR is only 2.47 when at certain time points like 36 months its as high as 14.49
Dr Kirolos Michael6:41 pm
That’s because the odds doesn’t factor time I guess
BethC6:42 pm
There was no impact on overall survival from what I read, though functionally RARP was much better
BethC6:42 pm
In terms of quality of life post-treatment
Dr Kirolos Michael6:42 pm
That’s right Beth. There was no difference in the overall survival
Dr Kirolos Michael6:46 pm
Also Americos, those ORs in the table are relative to the OR at 1 month. So this isn’t the absolute odds ratio, it’s a relative odds ratio (compared to at 1 month etc)
Dr Kirolos Michael6:47 pm
How about satisfaction?
sharanniyan6:49 pm
RARP group were happier
Dr Kirolos Michael6:49 pm
Great
sharanniyan6:49 pm
Due to the better continency and potency most likely
Dr Kirolos Michael6:49 pm
So that summarises the results
Dr Kirolos Michael6:49 pm
Shall we start listing the positives of this study?
Dr Kirolos Michael6:49 pm
If everyone can think of one positive thing about this study
dianaomari6:50 pm
Control of variables e.g. same surgeon, same technique
Dr Kirolos Michael6:50 pm
Very good
sharanniyan6:50 pm
Its an RCT with a fairly sizeable n number
leah.argus6:50 pm
The cohorts were very comparable in terms of stage of disease
BethC6:51 pm
The study period being 5 years allowed a good follow up period to accurately assess patient satisfaction and long-term side effects/complications if any
Dr Kirolos Michael6:51 pm
All very good points
leah.argus6:51 pm
^Which is an uncommon occurrence according to their literature review Beth
Dr Kirolos Michael6:51 pm
so going back to the size of the study, is it large?
dianaomari6:51 pm
I wouldn’t say large
sharanniyan6:51 pm
I don’t think large enough
Ashka6:52 pm
It is not large (just 120 patients)
Americos Argyriou6:52 pm
I think thats actually a pitfall of this study… 120 is not enough for a comparison between 2 operations where the negative outcomes are really rare
leah.argus6:52 pm
For example they needed to do Fisher’s exact instead of Chi^2 in their statistics, which usually is the result of not enough data for a Chi^2
leah.argus6:52 pm
(I think)
BethC6:52 pm
^^good point
Dr Kirolos Michael6:52 pm
I agree. 120 is quite small. But you can argue that if you want to control a lot of factors for example making sure everyone is operated on by the same surgeon, you are going to have to live with a small sample size etc.
dianaomari6:53 pm
That’s true
Dr Kirolos Michael6:53 pm
so there are trade-offs here
sharanniyan6:53 pm
Would a multi centre RCT have been a better alternative?
leah.argus6:53 pm
I think that would give a better representation of real-life outcomes
Dr Kirolos Michael6:53 pm
good point about the fisher exact test suggesting it wasn’t a large enough sample size for a chi square
Dr Kirolos Michael6:54 pm
so in the discussion, did anyone notice anything about a bigger study?
sharanniyan6:55 pm
No significant difference found in that bigger study
sharanniyan6:55 pm
For continence
Dr Kirolos Michael6:55 pm
Absolutely, so in a retrospective study that compared 1,377 LRP vs 1,009 RARP patients, they found no difference in continence…
leah.argus6:56 pm
However they didn’t mention the Cochrane review from September 2017 which tend to demonstrate good quality evidence
Dr Kirolos Michael6:56 pm
It raises questions. Can we apply the findings of this study to the wider population of patients with prostate cancer confined to the prostate?
Dr Kirolos Michael6:56 pm
Can you tell us about this Cochrane review Leah?
BethC6:57 pm
I believe the study definitely justifies possibly a larger study into RARP vs LRP as it shows no negative impact on survival
BethC6:58 pm
But i’m not sure if the study is strong enough to change guidelines
BethC6:58 pm
I may be wrong though!
Dr Kirolos Michael6:59 pm
I completely agree. So if we are looking at just this one study in isolation, it looks very promising, but with a sample of 120, you probably wouldn’t be changing national guidelines based on this one study
leah.argus7:00 pm
So I found the Cochrane review when I had a quick browse of the EAU guidelines on the subject of radical prostectomy (https://www.ncbi.nlm.nih.gov/pubmed/28895658) It seems to confirm the notion that high-quality evidence on the LRP vs RARP is scarce, but previous evidence shows no difference including for continence and potency
leah.argus7:00 pm
Sorry, took me a minute to type
sharanniyan7:00 pm
Further, it would also depend on the centre to have the ability to do a RARP in the first place before considering changing of guidelines
Dr Kirolos Michael7:01 pm
Great point Leah
dianaomari7:01 pm
True it’s very expensive
Dr Kirolos Michael7:01 pm
Absolutely, these Da Vinci robots are very expensive and costly for maintenance
Dr Kirolos Michael7:01 pm
and require a surgeon who is we trained in robotic assisted prostatectomies
Americos Argyriou7:02 pm
I agree with Beth and also, if a larger multicentre study found no difference in continence then we need to consider whether this surgeon’s technique is the factor causing these results
leah.argus7:02 pm
A finding of “non-inferiority” of RARP in terms of survival, oncological outcomes, functional outcomes etc can be a useful finding on it’s own too
Dr Kirolos Michael7:02 pm
The technical skills of the surgeon are going to play a role here and factors like how many of these operations are being performed by each centre. The bigger centres will have more experience, perhaps better outcomes etc.
Sacha Chiuta7:02 pm
I was going to ask, if the larger multi centre study found no difference does it not call into question whether this study’s results are reliable
Sacha Chiuta7:03 pm
It was a relatively small cohort of patients
Sacha Chiuta7:03 pm
Same surgeon same centre
BethC7:03 pm
Good point Leah, even though the study can’t confirm which is superior, the lack of negative impact on those factors can be taken as a step forward
Dr Kirolos Michael7:03 pm
That’s a good point as well Leah. Perhaps there are other advantages to RARP compared to laparoscopic that were not assessed in this study
Dr Kirolos Michael7:03 pm
Absolutely Sacha
Americos Argyriou7:04 pm
True. I think a big issue with comparing 2 techniques where 1 is super recent is that it means that surgeons are more experienced with the Lap technique so results will always favor it until more centres develop more experience with using it in their Teams
Dr Kirolos Michael7:04 pm
It could mean that this particular surgeon just has very good outcomes with RARP
Americos Argyriou7:04 pm
Yeah I agree with that
Dr Kirolos Michael7:04 pm
Again another very good point Americos
sharanniyan7:05 pm
This particular type of patient cohort could also be well suited for an RARP
Dr Kirolos Michael7:05 pm
This is a newer technique compared to laparoscopic prostatectomy
sharanniyan7:05 pm
Compared to those with further disease progression
Dr Kirolos Michael7:06 pm
The final point I wanted to make with regards to patient satisfaction
Dr Kirolos Michael7:06 pm
The patients having the RARP are told that this is the newest and latest technique. Perhaps this could influence their satisfaction, knowing that they have had the cutting edge surgical technique.
Americos Argyriou7:08 pm
They didn’t attempt to blind the intervention. Possibly that could have been done.
Americos Argyriou7:08 pm
The patients knowing might definitely affect their morale/satisfaction post-op
Dr Kirolos Michael7:09 pm
In summary, NICE guidelines are now recommending RARP to be used increasingly and have issued suggestions about things like which centres should use them, minimum number of procedures to be done per centre in order to continue with this type of surgery. So it is being increasingly adopted. And like I said, even in DGHs that have urology centres like Stepping Hill perform robot-assisted radical prostatectomies on a weekly basis.
BethC7:09 pm
How can you control for the placebo effect in surgical trials? Is it possible
Dr Kirolos Michael7:09 pm
From an ethical point of view, can you consent a patient to blindly have one operation or the other?
Dr Kirolos Michael7:09 pm
Would you get approval from an ethics committee for blinding of that nature?
BethC7:10 pm
Consent would be null and void, it’s a difficult one to justify
Dr Kirolos Michael7:10 pm
I don’t think it would ever be possible
Ashka7:10 pm
Yo
Ashka7:10 pm
Sorry
Ashka7:10 pm
I was typing
Dr Kirolos Michael7:10 pm
Any more comments before we wrap up?
Americos Argyriou7:10 pm
if both procedures have the same risk profiles then you could consent them for both no?
Americos Argyriou7:10 pm
I thought that could be done
Dr Kirolos Michael7:11 pm
No because you have to consent specifically for the surgery that you are doing. It has to be specific and you can’t really deviate too much
Americos Argyriou7:11 pm
But I see the issues raised…
Americos Argyriou7:11 pm
I see
BethC7:12 pm
Thank you for talking us through the paper Kirolos! It was an interesting one to start off with
Americos Argyriou7:12 pm
Yup, it was an interesting paper!
Dr Kirolos Michael7:12 pm
And patients should have the right to know what they’re having even if they consented to be randomly allocated. Furthermore, after the operation, even if you could somehow blind ethically, they would need to find out what they have had done and that may impact satisfaction etc.
leah.argus7:12 pm
Thank you! Great discussion points Dr Michael
Ashka7:12 pm
Thank you very much! That was very interesting and informative
dianaomari7:13 pm
Thank you !!!
Dr Kirolos Michael7:13 pm
Thanks very much guys. I was very impressed with discussion. I think you’ve all hit all the main points. I hope you found it interesting. Like I said, I’m trying to choose papers with an interesting theme. They aren’t necessarily the best studies etc.
sharanniyan7:13 pm
Very interesting paper and discussion, thanks Dr Michael
Sacha Chiuta7:13 pm
Thank you so much Dr. Michael such an interesting discussion
Dr Kirolos Michael7:13 pm
See you all next time. I send you guys some feedback forms for the next session
Won7:13 pm
Thank you so much!
Sacha Chiuta7:13 pm
Thank you Beth and LEAH
Dr Kirolos Michael7:14 pm
And please call me Kirolos
sharanniyan7:15 pm
Forgot to put my email in, Sharanniyan Ragavan, 2nd year, sharanniyan.ragavan@student.manchester.ac.uk
Total number = 9
BethCReply
Hi everyone
Won5:57 pm
Hello, I’m Won Young
leah.argus5:57 pm
Hi there, I’m Leah
dianaomari5:58 pm
Hi, I am DIana
dianaomari5:58 pm
Diana*
Dr Kirolos Michael5:59 pm
Hi everyone! We’ll start in a few minutes once more people have joined
Americos Argyriou6:01 pm
Could everyone please write down you name, Year of study, Hospital and email for our records and for Certificates of Attendance!
Americos Argyriou6:02 pm
Hey guys, I’m Americos, Intercalator 3rd/4th year, MRI, amerikos.argyriou@student.manchester.ac.uk
Won6:02 pm
I’m Won Young, Year 2, won.yoon@student.manchester.ac.uk
BethC6:02 pm
Beth, Year 4 Salford Royal, bethan.clayton@student.manchester.ac.uk
dianaomari6:03 pm
Hello, I’m Diana Al-Omari, 3rd year, MRI, diana.omari@student.manchester.ac.uk
leah.argus6:03 pm
Leah, 4th year, MFT Wytheshawe, leah.argus@student.manchester.ac.uk
BethC6:04 pm
Has everyone read the paper? Was it an okay read?
dianaomari6:04 pm
Yes it was quite interesting
leah.argus6:04 pm
It’s quite clear in its aims and outcomes
Dr Kirolos Michael6:05 pm
I’m Kirolos, FY2 doctor at stepping hill
Dr Kirolos Michael6:05 pm
is everyone ready to make a start?
nmp246:05 pm
Nora, 4th year, SRFT, eleanor.palmer-2@student.manchester.ac.uk
leah.argus6:06 pm
I’m happy to get started
dianaomari6:06 pm
Me too
Dr Kirolos Michael6:06 pm
So the aim of these sessions is to give a taster into the world of medical research. Each session, we will look a different surgical speciality.
Dr Kirolos Michael6:07 pm
This week, I have chosen urology and selected a paper that looks at comparing robot-assisted vs. laparoscopic prostatectomy in terms of the 5yr outcome
Dr Kirolos Michael6:08 pm
Hopefully if was an interesting topic
Dr Kirolos Michael6:08 pm
Can anyone summarise the aim of the study?
leah.argus6:09 pm
It seems to be a prospective randomised study (1 year of data collection, n=120 patients, 5 years of follow up), comparing functional, oncological and patient satisfaction outcomes of robot assisted versus laparoscopic radical prostatectomy, finding improvement in functional outcomes for RARP
Dr Kirolos Michael6:10 pm
great
Dr Kirolos Michael6:12 pm
So a bit of background. Radical prostatectomy involves resecting the entirety of the prostate for localised prostate cancer, with curative intent. In the past, this used to be done as an open surgery, then laparoscopic surgery became favoured and most recently, robot-assisted prostatectomy is currently the Gold-standard. We even have a robot in urology centres like Stepping Hill where I work
Dr Kirolos Michael6:12 pm
What were the functional, oncological & patient satisfaction outcomes that they assessed?
dianaomari6:13 pm
continence, potency, PSA, were functional
dianaomari6:13 pm
satisfaction and general health status
dianaomari6:13 pm
and survival rates for the oncological aspect?
dianaomari6:13 pm
I think
Americos Argyriou6:14 pm
PSA would come under oncological too I think
leah.argus6:14 pm
they assessed biochemical recurrence free survival as a parameter
Dr Kirolos Michael6:14 pm
Good. So functional measures were continence and potency (i.e. ability to achieve a satisfactory erection)
Dr Kirolos Michael6:14 pm
How well things function afterwards
Dr Kirolos Michael6:15 pm
The PSA is more of an oncological marker of recurrence, that is the biochemical marker of recurrence
dianaomari6:15 pm
Makes sense
Dr Kirolos Michael6:16 pm
After surgery, follow up would involve prostate specific antigen levels (PSA). If they start rising, it is an indicator of recurrence.
Dr Kirolos Michael6:16 pm
We’ve already touched a little on the study type. Would someone like to summarise the methodology?
dianaomari6:17 pm
120 patients with prostate cancer were enrolled and randomly assigned to RARP or LRP
dianaomari6:18 pm
The same surgeon performed all the operations
Americos Argyriou6:18 pm
Single centre, single surgeon as well
Americos Argyriou6:18 pm
yeah
dianaomari6:18 pm
Yes
Dr Kirolos Michael6:19 pm
Very good.
leah.argus6:19 pm
That’s a bit of a limitation
Americos Argyriou6:19 pm
They also set guidelines for the type of stage tumour they’re including into the trial
Dr Kirolos Michael6:19 pm
So the key point is that this was a randomised-controlled trial. Single centre. Single surgeon.
Dr Kirolos Michael6:19 pm
So which tumours were only included?
Americos Argyriou6:20 pm
As in only T1-2 N0 M0
Dr Kirolos Michael6:20 pm
I agree about the limitation Leah, we’ll come onto that in a little bit
Dr Kirolos Michael6:20 pm
That’s right Americos. Does anyone know what that TNM staging means?
sharanniyan6:20 pm
grade, nodal involvement and distant metastasis?
Dr Kirolos Michael6:21 pm
That’s correct. But in terms of a T1-2, N0, M0 etc.?
sharanniyan6:22 pm
they didn’t have nodal involvement or distant metastasis and were fairly small tumours?
sharanniyan6:22 pm
small-medium size perhaps
Dr Kirolos Michael6:22 pm
absolutely
leah.argus6:22 pm
T1-2 means no extraprostatic involvement i think
Won6:22 pm
T1-2 would be 2cm, N0 would be negative lymph nodes, and M0 would be no distant metastases
Dr Kirolos Michael6:23 pm
They were confined to the prostate
leah.argus6:24 pm
Was this determined clinically or pathologically (pT) in the study?
Dr Kirolos Michael6:24 pm
So Won, the T in the TNM staging of prostate cancer doesn’t involve size. It is to do with if it is confined to the prostate or locally invasive into nearby structures or organs etc. The T is different for different cancers. In some it is to with the size of the tumour etc.
Won6:25 pm
Sure
Dr Kirolos Michael6:25 pm
Good question Leah. So int he study design, it says it was pathologically confirmed
Dr Kirolos Michael6:26 pm
So required a biopsy (usually transperineal these days, but transrectal in the past)
BethC6:26 pm
Are we ready to start?
BethC6:27 pm
Sorry my laptop hadn’t refreshed at all
Ashka6:27 pm
Hi it’s Ashka. Sorry for being late. Traffic was really bad from wigan
Americos Argyriou6:27 pm
hahaha
Americos Argyriou6:27 pm
(sorry Beth)
Dr Kirolos Michael6:27 pm
haha I thought I got the wrong start time for a second?
Dr Kirolos Michael6:27 pm
Shall we move on to the results
Dr Kirolos Michael6:28 pm
so does anyone have any questions about the study design & aims etc.?
BethC6:28 pm
Of course, sorry about that
Dr Kirolos Michael6:29 pm
can anyone summarise the functional differences?
leah.argus6:29 pm
Were variables like blood loss and length of hospital stay recorded? These could affect the superiority of either
sharanniyan6:30 pm
continence was significant
Dr Kirolos Michael6:30 pm
That’s right, continence was significant. Does any one have any numbers to hand, maybe can explain what they mean?
dianaomari6:31 pm
the probability of achieving continence over time was more than doubled in the RARP group compared to the LRP group (odds ratio [OR] 2.47; 95% confidence interval [CI] 1.15–5.31; p = 0.021).
Dr Kirolos Michael6:31 pm
Fantastic
sharanniyan6:31 pm
potency was doubled as well
leah.argus6:32 pm
Odds ratio here implies that patients undergoing RARP were 2.47x more likely to achieve continence, right?
sharanniyan6:32 pm
slightly more than doubled in fact
Dr Kirolos Michael6:32 pm
Is everyone up to date with what an odds ratio is?
sharanniyan6:32 pm
2.35x
Dr Kirolos Michael6:32 pm
Exactly
Dr Kirolos Michael6:32 pm
How do we calculate the odds ratio generally speaking?
leah.argus6:33 pm
Mantel-Cox regression is one way of doing it
BethC6:34 pm
I’m not entirely sure actually, could you explain if that’s okay?
Dr Kirolos Michael6:34 pm
That’s one way of analysing a hazard ratio not an odds ratio
Dr Kirolos Michael6:34 pm
So essentially
Americos Argyriou6:35 pm
Simplifying it down you can just do the fraction of those with continence in one arm and divide it by the fraction of those with continence in the other
Americos Argyriou6:35 pm
That’ll give you the OR
Dr Kirolos Michael6:36 pm
To calculate an odds ratio, you calculate the probability of event in group A and the probability of event in group B (odds of the event in each group). Then you divide the odds of your intervention group over the comparator group
Dr Kirolos Michael6:37 pm
So that is correct Americos
BethC6:37 pm
That makes sense thank you!
Americos Argyriou6:37 pm
I think you put it more clearly
sharanniyan6:37 pm
How is that different from a hazard ratio?
Ashka6:37 pm
Thank you
Dr Kirolos Michael6:37 pm
So as everyone has said, you are >2x more likely to be continent & potent with RARP vs LRP
Dr Kirolos Michael6:39 pm
So the hazard ratio is time dependent. It’s a time to event analysis that a little more complicated compared to the odds ratio. You are essentially seeing at a chosen point in time, what is the likely hood of the event occurring up to that particular time. The odds ratio doesn’t like at time. It is just the probability of it happening at all if that makes sense
sharanniyan6:39 pm
Oh I see, thank you
leah.argus6:39 pm
Thanks for clarifying
Dr Kirolos Michael6:40 pm
Great
Dr Kirolos Michael6:40 pm
How about in terms of the oncological outcomes like survival. Were there any differences between the two?
Americos Argyriou6:40 pm
Strange how the overall contience OR is only 2.47 when at certain time points like 36 months its as high as 14.49
Dr Kirolos Michael6:41 pm
That’s because the odds doesn’t factor time I guess
BethC6:42 pm
There was no impact on overall survival from what I read, though functionally RARP was much better
BethC6:42 pm
In terms of quality of life post-treatment
Dr Kirolos Michael6:42 pm
That’s right Beth. There was no difference in the overall survival
Dr Kirolos Michael6:46 pm
Also Americos, those ORs in the table are relative to the OR at 1 month. So this isn’t the absolute odds ratio, it’s a relative odds ratio (compared to at 1 month etc)
Dr Kirolos Michael6:47 pm
How about satisfaction?
sharanniyan6:49 pm
RARP group were happier
Dr Kirolos Michael6:49 pm
Great
sharanniyan6:49 pm
Due to the better continency and potency most likely
Dr Kirolos Michael6:49 pm
So that summarises the results
Dr Kirolos Michael6:49 pm
Shall we start listing the positives of this study?
Dr Kirolos Michael6:49 pm
If everyone can think of one positive thing about this study
dianaomari6:50 pm
Control of variables e.g. same surgeon, same technique
Dr Kirolos Michael6:50 pm
Very good
sharanniyan6:50 pm
Its an RCT with a fairly sizeable n number
leah.argus6:50 pm
The cohorts were very comparable in terms of stage of disease
BethC6:51 pm
The study period being 5 years allowed a good follow up period to accurately assess patient satisfaction and long-term side effects/complications if any
Dr Kirolos Michael6:51 pm
All very good points
leah.argus6:51 pm
^Which is an uncommon occurrence according to their literature review Beth
Dr Kirolos Michael6:51 pm
so going back to the size of the study, is it large?
dianaomari6:51 pm
I wouldn’t say large
sharanniyan6:51 pm
I don’t think large enough
Ashka6:52 pm
It is not large (just 120 patients)
Americos Argyriou6:52 pm
I think thats actually a pitfall of this study… 120 is not enough for a comparison between 2 operations where the negative outcomes are really rare
leah.argus6:52 pm
For example they needed to do Fisher’s exact instead of Chi^2 in their statistics, which usually is the result of not enough data for a Chi^2
leah.argus6:52 pm
(I think)
BethC6:52 pm
^^good point
Dr Kirolos Michael6:52 pm
I agree. 120 is quite small. But you can argue that if you want to control a lot of factors for example making sure everyone is operated on by the same surgeon, you are going to have to live with a small sample size etc.
dianaomari6:53 pm
That’s true
Dr Kirolos Michael6:53 pm
so there are trade-offs here
sharanniyan6:53 pm
Would a multi centre RCT have been a better alternative?
leah.argus6:53 pm
I think that would give a better representation of real-life outcomes
Dr Kirolos Michael6:53 pm
good point about the fisher exact test suggesting it wasn’t a large enough sample size for a chi square
Dr Kirolos Michael6:54 pm
so in the discussion, did anyone notice anything about a bigger study?
sharanniyan6:55 pm
No significant difference found in that bigger study
sharanniyan6:55 pm
For continence
Dr Kirolos Michael6:55 pm
Absolutely, so in a retrospective study that compared 1,377 LRP vs 1,009 RARP patients, they found no difference in continence…
leah.argus6:56 pm
However they didn’t mention the Cochrane review from September 2017 which tend to demonstrate good quality evidence
Dr Kirolos Michael6:56 pm
It raises questions. Can we apply the findings of this study to the wider population of patients with prostate cancer confined to the prostate?
Dr Kirolos Michael6:56 pm
Can you tell us about this Cochrane review Leah?
BethC6:57 pm
I believe the study definitely justifies possibly a larger study into RARP vs LRP as it shows no negative impact on survival
BethC6:58 pm
But i’m not sure if the study is strong enough to change guidelines
BethC6:58 pm
I may be wrong though!
Dr Kirolos Michael6:59 pm
I completely agree. So if we are looking at just this one study in isolation, it looks very promising, but with a sample of 120, you probably wouldn’t be changing national guidelines based on this one study
leah.argus7:00 pm
So I found the Cochrane review when I had a quick browse of the EAU guidelines on the subject of radical prostectomy (https://www.ncbi.nlm.nih.gov/pubmed/28895658) It seems to confirm the notion that high-quality evidence on the LRP vs RARP is scarce, but previous evidence shows no difference including for continence and potency
leah.argus7:00 pm
Sorry, took me a minute to type
sharanniyan7:00 pm
Further, it would also depend on the centre to have the ability to do a RARP in the first place before considering changing of guidelines
Dr Kirolos Michael7:01 pm
Great point Leah
dianaomari7:01 pm
True it’s very expensive
Dr Kirolos Michael7:01 pm
Absolutely, these Da Vinci robots are very expensive and costly for maintenance
Dr Kirolos Michael7:01 pm
and require a surgeon who is we trained in robotic assisted prostatectomies
Americos Argyriou7:02 pm
I agree with Beth and also, if a larger multicentre study found no difference in continence then we need to consider whether this surgeon’s technique is the factor causing these results
leah.argus7:02 pm
A finding of “non-inferiority” of RARP in terms of survival, oncological outcomes, functional outcomes etc can be a useful finding on it’s own too
Dr Kirolos Michael7:02 pm
The technical skills of the surgeon are going to play a role here and factors like how many of these operations are being performed by each centre. The bigger centres will have more experience, perhaps better outcomes etc.
Sacha Chiuta7:02 pm
I was going to ask, if the larger multi centre study found no difference does it not call into question whether this study’s results are reliable
Sacha Chiuta7:03 pm
It was a relatively small cohort of patients
Sacha Chiuta7:03 pm
Same surgeon same centre
BethC7:03 pm
Good point Leah, even though the study can’t confirm which is superior, the lack of negative impact on those factors can be taken as a step forward
Dr Kirolos Michael7:03 pm
That’s a good point as well Leah. Perhaps there are other advantages to RARP compared to laparoscopic that were not assessed in this study
Dr Kirolos Michael7:03 pm
Absolutely Sacha
Americos Argyriou7:04 pm
True. I think a big issue with comparing 2 techniques where 1 is super recent is that it means that surgeons are more experienced with the Lap technique so results will always favor it until more centres develop more experience with using it in their Teams
Dr Kirolos Michael7:04 pm
It could mean that this particular surgeon just has very good outcomes with RARP
Americos Argyriou7:04 pm
Yeah I agree with that
Dr Kirolos Michael7:04 pm
Again another very good point Americos
sharanniyan7:05 pm
This particular type of patient cohort could also be well suited for an RARP
Dr Kirolos Michael7:05 pm
This is a newer technique compared to laparoscopic prostatectomy
sharanniyan7:05 pm
Compared to those with further disease progression
Dr Kirolos Michael7:06 pm
The final point I wanted to make with regards to patient satisfaction
Dr Kirolos Michael7:06 pm
The patients having the RARP are told that this is the newest and latest technique. Perhaps this could influence their satisfaction, knowing that they have had the cutting edge surgical technique.
Americos Argyriou7:08 pm
They didn’t attempt to blind the intervention. Possibly that could have been done.
Americos Argyriou7:08 pm
The patients knowing might definitely affect their morale/satisfaction post-op
Dr Kirolos Michael7:09 pm
In summary, NICE guidelines are now recommending RARP to be used increasingly and have issued suggestions about things like which centres should use them, minimum number of procedures to be done per centre in order to continue with this type of surgery. So it is being increasingly adopted. And like I said, even in DGHs that have urology centres like Stepping Hill perform robot-assisted radical prostatectomies on a weekly basis.
BethC7:09 pm
How can you control for the placebo effect in surgical trials? Is it possible
Dr Kirolos Michael7:09 pm
From an ethical point of view, can you consent a patient to blindly have one operation or the other?
Dr Kirolos Michael7:09 pm
Would you get approval from an ethics committee for blinding of that nature?
BethC7:10 pm
Consent would be null and void, it’s a difficult one to justify
Dr Kirolos Michael7:10 pm
I don’t think it would ever be possible
Ashka7:10 pm
Yo
Ashka7:10 pm
Sorry
Ashka7:10 pm
I was typing
Dr Kirolos Michael7:10 pm
Any more comments before we wrap up?
Americos Argyriou7:10 pm
if both procedures have the same risk profiles then you could consent them for both no?
Americos Argyriou7:10 pm
I thought that could be done
Dr Kirolos Michael7:11 pm
No because you have to consent specifically for the surgery that you are doing. It has to be specific and you can’t really deviate too much
Americos Argyriou7:11 pm
But I see the issues raised…
Americos Argyriou7:11 pm
I see
BethC7:12 pm
Thank you for talking us through the paper Kirolos! It was an interesting one to start off with
Americos Argyriou7:12 pm
Yup, it was an interesting paper!
Dr Kirolos Michael7:12 pm
And patients should have the right to know what they’re having even if they consented to be randomly allocated. Furthermore, after the operation, even if you could somehow blind ethically, they would need to find out what they have had done and that may impact satisfaction etc.
leah.argus7:12 pm
Thank you! Great discussion points Dr Michael
Ashka7:12 pm
Thank you very much! That was very interesting and informative
dianaomari7:13 pm
Thank you !!!
Dr Kirolos Michael7:13 pm
Thanks very much guys. I was very impressed with discussion. I think you’ve all hit all the main points. I hope you found it interesting. Like I said, I’m trying to choose papers with an interesting theme. They aren’t necessarily the best studies etc.
sharanniyan7:13 pm
Very interesting paper and discussion, thanks Dr Michael
Sacha Chiuta7:13 pm
Thank you so much Dr. Michael such an interesting discussion
Dr Kirolos Michael7:13 pm
See you all next time. I send you guys some feedback forms for the next session
Won7:13 pm
Thank you so much!
Sacha Chiuta7:13 pm
Thank you Beth and LEAH
Dr Kirolos Michael7:14 pm
And please call me Kirolos
sharanniyan7:15 pm
Forgot to put my email in, Sharanniyan Ragavan, 2nd year, sharanniyan.ragavan@student.manchester.ac.uk